Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
16th February 2021 | Thomas Gad | 4,000 | Open or private sale | $47.09 | $188,366.80 |
16th February 2021 | Thomas Gad | 7,000 | Open or private sale | $47.08 | $329,555.80 |
16th February 2021 | Thomas Gad | 7,000 | Exercise of derivative | $2.00 | $14,000.00 |
9th February 2021 | James Healy | 450,000 | Open or private purchase | $20.00 | $9,000,000.00 |
9th February 2021 | James Healy | 1,200,228 | Conversion of derivative | $0.00 | |
9th February 2021 | James Healy | 1,104,209 | Conversion of derivative | $0.00 | |
19th January 2021 | David N Gill | 2,000 | Exercise of derivative | $11.16 | $22,320.00 |
19th January 2021 | Thomas Gad | 7,000 | Exercise of derivative | $2.00 | $14,000.00 |
19th January 2021 | David N Gill | 2,000 | Open or private sale | $46.52 | $93,045.20 |
19th January 2021 | Thomas Gad | 4,000 | Open or private sale | $46.56 | $186,230.40 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Y-mAbs Therapeutics is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company's services include discovery, protein engineering, clinical and regulatory.
26th February 2021
18th February 2021